Navigation Links
Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial
Date:12/4/2009

rolide, an established treatment for prostate cancer, FIRMAGON does not induce an initial testosterone surge. FIRMAGON is administered monthly by subcutaneous injection. The starting dose is 240 mg, followed by monthly maintenance doses of 80 mg. FIRMAGON is available for order through traditional and specialty pharmacy distributors. The average monthly cost of one year of FIRMAGON treatment is comparable to other hormone treatments for prostate cancer.

The most commonly observed adverse reactions during FIRMAGON therapy included injection site reactions (e.g. pain, erythema, swelling or induration) and other androgen deprivation therapy (ADT) associated side effects including hot flashes, increased weight and fatigue. Ninety-nine percent of these observed adverse reactions were Grade 1 or 2 (mild to moderate). Specifically relating to the injection site adverse reactions, most were transient, of mild to moderate intensity, occurred primarily with the starting dose and led to few discontinuations (<1%). Grade 3 (severe) injection site reactions occurred in two percent or less of patients receiving FIRMAGON.

FIRMAGON is contraindicated in patients with known hypersensitivity to degarelix or to any of the product components. FIRMAGON is not indicated in women or pediatric patients. Long-term ADT prolongs the QT interval. Physicians should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, electrolyte abnormalities, or congestive heart failure and in patients taking Class IA (e.g. quinidine, procainamide) or Class III (e.g. amiodarone, sotalol) antiarrhythmic medications.

About Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharmaceutical company. Ferring Pharmaceuticals offers a line of infertility, urology, and orthopaedic produc
'/>"/>

SOURCE Ferring Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy
2. BSGI Makes Significant Impact on Detection of Breast Cancer in Patients with Negative Mammographic Findings
3. Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation
4. Unindicated CT Series Result in Unnecessary Radiation Exposure for Patients
5. Philips Responds to Industry Concerns With Focus on Radiation Dose Management Products Designed for Clinicians and Patients
6. Caldolor(R) (Ibuprofen) Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients
7. Proteon Initiates Second Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients
8. Echo Therapeutics Announces Positive Results of a Clinical Study Testing Symphony(TM) tCGM System in Patients with Type 1 and Type 2 Diabetes
9. Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals siRNA Drugs In Multiple Fully Enrolled Clinical Trials
10. New Updates to AHA/ACC/SCAI Clinical Guidelines Recommend Treatment with Effient(R) for Patients with Acute Coronary Syndromes Managed with PCI
11. Mersana Therapeutics Provides Clinical Update from Ongoing Phase 1 Study of XMT-1001 in Patients with Advanced Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... March 27, 2015 Zimmer Holdings, Inc. (NYSE and SIX: ZMH) ... ® Complete Knee System. ... th year since Zimmer first introduced the NexGen knee ... date, more than five million implantations of the NexGen knee ... the NexGen knee demonstrates the importance of design innovation and ...
(Date:3/27/2015)... Report Details  New study shows ... What does the future hold for top companies ... new report shows you potential revenues to 2025, assessing ... 242-page report provides 185 tables, charts, and graphs. Discover ... future market prospects. Our new study lets you assess ...
(Date:3/27/2015)... 2015 The International Myeloma Foundation (IMF) – ... working toward prevention and a cure – today commended ... federal resolution (H. Res. 174) that supports the designation ... Myeloma Awareness Month." Currently there are more ... than 110,000 new cases are diagnosed yearly, according to ...
Breaking Medicine Technology:Zimmer Celebrates Key Milestones For NexGen Complete Knee System 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2
... WASHINGTON, Sept. 1, 2011 Lung Cancer ... approval of Xalkori (crizotinib) with non-small cell lung cancer ... based on data from two clinical trials, both of ... Xalkori targets the echinoderm microtubule-associated protein-like 4-anaplastic ...
... Sept. 1, 2011 Roche Diabetes Care, makers of ... is proud to host its second annual Infusion Site ... highlight the importance of proper infusion site management for ... 1 diabetes who use an insulin pump. ...
Cached Medicine Technology:New Drug Approved for Treatment of Non Small Cell Lung Cancer in Specific Patient Population 2Roche Diabetes Care Celebrates Second Annual Infusion Site Awareness Week, Aug. 29-Sept. 4 2Roche Diabetes Care Celebrates Second Annual Infusion Site Awareness Week, Aug. 29-Sept. 4 3
(Date:3/29/2015)... North American Seminars receives Texas Board ... Education Courses . , Utilizing Pilates to ... TPTA, approval # 56399TX      , The Interactive ... complex - 10.5 hours - Texas Board of Physical ... Treatment of the SI Joint - 10 hours - ...
(Date:3/28/2015)... "Necrorun" was featured on NewsWatch as part of ... latest and coolest applications on the market for iOS, ... and technology expert, conducted the app review and shared ... game with knights, nature, and peasants. , The ... to Eurogamer. The popularity of these games grew over ...
(Date:3/28/2015)... Emergency Medical Care (EMC), a New York ... commemorated its three-year anniversary of being the only 24/7 ... 24-hour urgent care, Emergency Medical Care offers its clients ... Emergency Medical Care’s Urgent Care NYC services ... injuries, ear infections, fevers, insect bites, burns, animal bites, ...
(Date:3/28/2015)... NV (PRWEB) March 28, 2015 One ... re-injury, according to research presented today at the American ... Day. The study examined the long term success of ... , “We examined survey data from 242 patients who ... author Justin P. Roe, MBBS, FRACS, from North Sydney ...
(Date:3/28/2015)... Andrew Hawley of Vintage Rock Posters Inc., ... posters. The Who and the Doors played together at the ... According to Hawley, “The Who toured the United States heavily ... campuses. Perhaps the most famous Who poster was a poster ... Doors on August 2, 1968 at the Singer Bowl in ...
Breaking Medicine News(10 mins):Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For&nbsp;Original 1960's Who Psychedelic Concert Posters. 2
... individuals, who constitute a rapidly growing population in the ... care utilization and cost. Yet more than ... age or age-related conditions, according to a new study ... the University of Michigan. "These findings are ...
... an inexpensive, FDA-approved hypertension medication may improve the ... In a report in the early edition of ... , Massachusetts General Hospital (MGH) investigators describe experiments ... the network of collagen fibers that characterizes most ...
... available in French . Montreal, February 2, ... (LGB) are at far higher risk for severe mental health ... suggests that the stress of being rejected or victimized because ... and bisexuals. Recently published as a doctoral thesis ...
... German . Lung tumors are the number one ... is lung cancer. Each year, there are 50,000 new cases of ... detected, the greater the chance of healing the patient. But early ... chronic inflammatory reactions. To get a more complete diagnosis, the patient ...
... thought to be active in killing cells also promotes cellular ... of RIP1 is actually necessary for survival of septic injury, ... potential for developing new treatments for sepsis PROVIDENCE, ... protein that plays a dual role in the liver during ...
... Children who grow up in poverty have health problems as ... live in communities with more social cohesiveness and control get ... be obese as adolescents. The new study, published in ... Psychological Science, is part of a long-term examination of children ...
Cached Medicine News:Health News:Older adults often excluded from clinical trials 2Health News:Generic drug may improve the effectiveness of cancer nanotherapies 2Health News:Physiological impacts of homophobia 2Health News:Physiological impacts of homophobia 3Health News:Early detection of lung cancer 2Health News:The 'death switch' in sepsis also promotes survival 2Health News:Having a strong community protects adolescents from risky health behaviors 2
Lorgnette pinhole occluder...
9 inch double ended with one end black and the other end with 49 holes...
6 inch hand held occlcuder with 49 holes...
Double Ended Occluders...
Medicine Products: